{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:27:58Z","timestamp":1790141278984,"version":"4.0.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sodium zirconium cyclosilicate (SZC), a novel drug used for treating hyperkalaemia, is effective in reducing serum potassium levels. The effects of potassium adsorbents on the mortality and hyperkalaemia-associated hospitalisation rates remain unclear. We aimed to examine how mortality and hyperkalaemia-associated hospitalisation rates vary with usage of various potassium adsorbents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study used patients\u2019 data between April 2008 and August 2021 obtained from a large-scale Japanese medical claims database. Consecutive patients with chronic kidney disease (CKD) prescribed potassium adsorbents were enrolled and divided into three groups according to the adsorbent type [SZC, calcium polystyrene sulfonate (CPS), and sodium polystyrene sulfonate (SPS)] and were observed for 1 year. The primary outcome was a composite of mortality and hyperkalaemia-associated hospitalisation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 234, 54\u2009183, and 18\u2009692 patients were prescribed SZC, CPS, and SPS, respectively. The SZC group showed a higher event-free survival rate than the other two groups. The hazard ratio for the primary outcome in the CPS and SPS groups was similar in the analyses of the subgroups of patients who did not receive renal replacement therapy and those who received haemodialysis. The SZC group had a higher renin-angiotensin-aldosterone system inhibitors (RAASi) continuation rate compared to CPS and SPS groups, the difference being especially significant for SPS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This real-world study demonstrated the therapeutic effect of SZC in reducing mortality and hyperkalaemia-associated hospitalisations. The high RAASi continuation rate in the SZC group might be a contributing factor for improvement of the primary outcome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ckj\/sfae021","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T09:27:59Z","timestamp":1707989279000},"source":"Crossref","is-referenced-by-count":13,"title":["Mortality and hyperkalaemia-associated hospitalisation in patients with chronic kidney disease: comparison of sodium zirconium cyclosilicate and sodium\/calcium polystyrene sulfonate"],"prefix":"10.1093","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7072-208X","authenticated-orcid":false,"given":"Chikao","family":"Onogi","sequence":"first","affiliation":[{"name":"Department of Nephrology, Nagoya University, Graduate School of Medicine , Nagoya , Japan"},{"name":"Department of Cell Physiology, Nagoya University, Graduate School of Medicine , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nagoya University, Graduate School of Medicine , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nagoya University Hospital , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Furuhashi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nagoya University Hospital , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8858-632X","authenticated-orcid":false,"given":"Shoichi","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nagoya University, Graduate School of Medicine , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,20]]},"reference":[{"key":"2024022420273108500_bib1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1053\/j.ackd.2017.06.004","article-title":"Hyperkalemia and hypokalemia in CKD: prevalence, risk factors, and clinical outcomes","volume":"24","author":"Gilligan","year":"2017","journal-title":"Adv Chronic Kidney Dis"},{"key":"2024022420273108500_bib2","doi-asserted-by":"crossref","first-page":"iii12","DOI":"10.1093\/ndt\/gfz231","article-title":"Hyperkalemia in patients with chronic renal failure","volume":"34","author":"Seliger","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2024022420273108500_bib3","doi-asserted-by":"crossref","first-page":"R225","DOI":"10.1186\/cc11872","article-title":"Severe hyperkalemia requiring hospitalization: predictors of mortality","volume":"16","author":"An","year":"2012","journal-title":"Crit Care"},{"key":"2024022420273108500_bib4","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1016\/j.mayocp.2019.05.031","article-title":"Discontinuation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease","volume":"94","author":"Qiao","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"2024022420273108500_bib5","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2215\/CJN.05850809","article-title":"Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study","volume":"5","author":"Korgaonkar","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024022420273108500_bib6","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archinternmed.2009.132","article-title":"The frequency of hyperkalemia and its significance in chronic kidney disease","volume":"169","author":"Einhorn","year":"2009","journal-title":"Arch Intern Med"},{"key":"2024022420273108500_bib7","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1159\/000437151","article-title":"Serum potassium, end-stage renal disease and mortality in chronic kidney disease","volume":"41","author":"Nakhoul","year":"2015","journal-title":"Am J Nephrol"},{"key":"2024022420273108500_bib8","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2215\/CJN.01730215","article-title":"Association between serum potassium and outcomes in patients with reduced kidney function","volume":"11","author":"Luo","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024022420273108500_bib9","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1093\/ndt\/gfx312","article-title":"Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes-a Danish population-based cohort study","volume":"33","author":"Thomsen","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2024022420273108500_bib10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/kisup.2012.66","article-title":"Management of progression and complications of CKD","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"2024022420273108500_bib11","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.2215\/CJN.03640415","article-title":"Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD","volume":"10","author":"Lepage","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024022420273108500_bib12","doi-asserted-by":"crossref","first-page":"3000605231167516","DOI":"10.1177\/03000605231167516","article-title":"Efficacy and safety of calcium polystyrene sulfonate in patients with hyperkalemia and stage 3-5 non-dialysis chronic kidney disease: a single-center randomized controlled trial","volume":"51","author":"Wang","year":"2023","journal-title":"J Int Med Res"},{"key":"2024022420273108500_bib13","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1411487","article-title":"Sodium zirconium cyclosilicate in hyperkalemia","volume":"372","author":"Packham","year":"2015","journal-title":"N Engl J Med"},{"key":"2024022420273108500_bib14","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s10557-020-07134-2","article-title":"Effects and safety of a novel oral potassium-lowering drug-sodium zirconium cyclosilicate for the treatment of hyperkalemia: a systematic review and meta-analysis","volume":"35","author":"Zhang","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"2024022420273108500_bib15","first-page":"54","article-title":"Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: the randomized, placebo-controlled HARMONIZE-Global study","volume":"7","author":"Zannad","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2024022420273108500_bib16","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1681\/ASN.2019050450","article-title":"A phase 3b, randomized, double-blind, placebo-controlled study of sodium zirconium cyclosilicate for reducing the incidence of predialysis hyperkalemia","volume":"30","author":"Fishbane","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2024022420273108500_bib17","first-page":"402","article-title":"Colonic necrosis and perforation due to calcium polystyrene sulfonate in a uraemic patient: a case report","volume":"4","author":"Akagun","year":"2011","journal-title":"NDT Plus"},{"key":"2024022420273108500_bib18","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/hr.2009.44","article-title":"Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study","volume":"32","author":"Saruta","year":"2009","journal-title":"Hypertens Res"},{"key":"2024022420273108500_bib19","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"2024022420273108500_bib20","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"2024022420273108500_bib21","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","author":"Consensus Trial Study Group","year":"1987","journal-title":"N Engl J Med"},{"key":"2024022420273108500_bib22","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"SOLVD Investigators","year":"1991","journal-title":"N Engl J Med"},{"key":"2024022420273108500_bib23","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial\u2014The losartan Heart Failure Survival Study ELITE II","volume":"355","author":"Pitt","year":"2000","journal-title":"Lancet"},{"key":"2024022420273108500_bib24","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"2024022420273108500_bib25","doi-asserted-by":"crossref","first-page":"e0173542","DOI":"10.1371\/journal.pone.0173542","article-title":"Long-term efficacy of oral calcium polystyrene sulfonate for hyperkalemia in CKD patients","volume":"12","author":"Yu","year":"2017","journal-title":"PLoS One"},{"key":"2024022420273108500_bib26","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","article-title":"Renin-angiotensin system inhibition in advanced chronic kidney disease","volume":"387","author":"Bhandari","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfae021\/56723144\/sfae021.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/17\/2\/sfae021\/56753487\/sfae021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/17\/2\/sfae021\/56753487\/sfae021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T09:07:39Z","timestamp":1731316059000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfae021\/7611696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfae021","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2024,2,1]]},"article-number":"sfae021"}}